GSK Investigational Site

Salt (gerona) 17190

0 studies enrolling now · 2 studies all time

What they study most

Pulmonary Disease, Chronic Obstructive

Studies at this site

• A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD — Completed
• The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD — Completed